Institutional Repository in Medical Sciences
(IRMS – Nicolae Testemițanu SUMPh)

Hepatoprotective products according to State Medicine Nomenclature from Republic of Moldova

Show simple item record

dc.contributor.author Toma, Maria-Mirabela
dc.contributor.author Bors, Carolina
dc.date.accessioned 2020-07-13T06:40:31Z
dc.date.available 2020-07-13T06:40:31Z
dc.date.issued 2018
dc.identifier.citation TOMA, Maria-Mirabela, BORS, Carolina. Hepatoprotective products according to State Medicine Nomenclature from Republic of Moldova. In: MedEspera: the 7th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2018, p. 180-181. en_US
dc.identifier.uri https://medespera.asr.md/wp-content/uploads/Abastract-Book-2018.pdf
dc.identifier.uri http://repository.usmf.md/handle/20.500.12710/11271
dc.description Department of Pharmacology and Clinical Pharmacology, Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova en_US
dc.description.abstract Introduction. The acute and chronic hepatites remains to be the main problem for the humanity and also for R. Moldova, that´s why the evaluation of drugs with hepatoprotective action is esential, both from a medical and social point of view and also from an economic point of view. Hepatoprotective products are constituents capable of protecting the liver from the destructiv action of endogenous and exogenous factors. Aim of the study. Our main goal is to select all the hepatoprotective products that were recorded in R. Moldova, analyzing them according to the State Medicine Nomenclature(SMN). Materials and methods. For our research, as materials, were used: the SMN that contains 5137 drugs, available on Medicines and Medical Devices Agency (amed.md) and also the scientific literature and guides on the classification of hepatoprotective products. Results. Hepatoprotective products have a lot of 2.1% of the total number of medicine from the nomenclature (5137), the first in the list are the drugs with vegetal origins: Silymarin products - 31, followed by ursodeoxycholic acid products -18, amino acid products -17, phospholipids products -9, and other different groups own an amount of 32 products. At the moment, the following products are absent from the pharmaceutical market: amino acid derivatives: Betaina citrat, Ornitin aspartat; drugs which contain phospholipids: Fosfolip, Lipin, Eplir; drugs with a animal origins: Sirepar, Vitogepat; and also synthetic drugs. According to the pharmaceutical forms, the hepatoprotective can be presented in capsules-55%, followed by tablets-26%, injectable solution-11%, oral solutions-7% and just 1% for vegetal products. We mention that reported to the manufacturing, 43% of hepatoprotective products are produced by EU, and 16% are produced in R. Moldova, etc. Conclusion. The National Program to combat the viral hepatitis for the years 2017-2021 provides a reduction of 50% till 2021 of the incindence and prevalence for the acute and chronic hepatitis, including through the access of pacients with hepatitis to medical products and to quality treatment services. en_US
dc.language.iso en en_US
dc.publisher MedEspera en_US
dc.subject hepatoprotective en_US
dc.subject products en_US
dc.subject hepatitis en_US
dc.title Hepatoprotective products according to State Medicine Nomenclature from Republic of Moldova en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

  • MedEspera 2018
    The 7th International Medical Congress for Students and Young Doctors, May 3-5, 2018

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics